We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+30.71%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$326M
AUM Growth
+$72.3M
Cap. Flow
-$3.11M
Cap. Flow %
-0.95%
Top 10 Hldgs %
66.65%
Holding
46
New
15
Increased
5
Reduced
6
Closed
15

Top Buys

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$13.7M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$13.7M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.71M
4
DERM
Dermira, Inc.
DERM
+$8.05M
5
KA
Kineta, Inc. Common Stock
KA
+$8M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$21.8M
2
CYTK icon
Cytokinetics
CYTK
+$13.5M
3
XLRN
Acceleron Pharma
XLRN
+$12.6M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$9.51M
5
EPZM
Epizyme, Inc
EPZM
+$7.73M

Sector Composition

Rank Sector Weight
1 Healthcare 79.95%
2 Miscellaneous 20.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$682M
$44.6M 13.69%
3,355,516
+453,558
+16% +$5.3M
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$32.4M 9.93%
500,576
+61,191
+14% +$3.45M
BMY icon
3
CALL
Bristol-Myers Squibb
BMY
$136B
$27M 8.27%
+500,000
New +$32.1M
ASMB icon
4
Assembly Biosciences
ASMB
$694M
$21.2M 6.51%
245,264
– –
DERM
5
DELISTED
Dermira, Inc.
DERM
$17.7M 5.42%
522,000
+250,000
+92% +$8.05M
ARDX icon
6
Ardelyx
ARDX
$984M
$17M 5.2%
+1,310,023
New +$13.7M
KURA icon
7
Kura Oncology
KURA
$1.13B
$16.3M 5.01%
2,611,906
+146,620
+6% +$743K
FPRX
8
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$15M 4.62%
+286,612
New +$13.7M
KYNB
9
Kyntra Bio
KYNB
$32.5M
$14.2M 4.36%
27,447
-4,103
-13% -$1.93M
GILD icon
10
CALL
Gilead Sciences
GILD
$181B
$11.9M 3.64%
150,000
– –
AGN
11
CALL
DELISTED
Allergan plc
AGN
$11.5M 3.53%
50,000
– –
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.99B
$10.6M 3.24%
+200,000
New +$8.71M
KA
13
DELISTED
Kineta, Inc. Common Stock
KA
$9.39M 2.88%
+4,302
New +$8M
EXAS
14
PUT
DELISTED
Exact Sciences
EXAS
$9.29M 2.85%
+500,000
New +$8.81M
AKAO
15
DELISTED
Achaogen Inc
AKAO
$8.05M 2.47%
1,679,707
+107,999
+7% +$431K
CYTK icon
16
Cytokinetics
CYTK
$10B
$7.77M 2.38%
846,654
-1,293,043
-60% -$13.5M
KIN
17
DELISTED
Kindred Biosciences, Inc.
KIN
$7.15M 2.19%
1,432,765
– –
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.74B
$5.42M 1.66%
357,365
– –
ONC
19
BeOne Medicines Ltd
ONC
$41.5B
$5.04M 1.55%
163,470
-11,910
-7% -$346K
IRWD icon
20
CALL
Ironwood Pharmaceuticals
IRWD
$682M
$4.47M 1.37%
336,111
-358,200
-52% -$4.19M
ASND icon
21
Ascendis Pharma A/S
ASND
$16.3B
$4.41M 1.35%
+219,200
New +$3.62M
ONCE
22
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$4.12M 1.26%
+68,600
New +$3.95M
ADVM
23
DELISTED
Adverum Biotechnologies
ADVM
$3.89M 1.19%
+94,626
New +$3.59M
NBRV
24
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.87M 1.19%
2,196
-55
-2% -$106K
NTLA icon
25
Intellia Therapeutics
NTLA
$1.8B
$3.42M 1.05%
200,858
-109,837
-35% -$2.13M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2016 Portfolio in Review

As of Q3 2016, EcoR1 Capital held 46 positions worth $326M, up 28% from $254M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

EcoR1 Capital's Q3 2016 filing shows 15 new, 5 increased, 6 reduced and 15 closed positions. Its largest new stake was Ardelyx: 1,310,023 shares worth $17M. The largest sale was Travere Therapeutics, an estimated $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q3 2016 buy was Ardelyx: 1,310,023 shares worth $17M.
  • EcoR1 Capital added most to Dermira, Inc. in Q3 2016, an estimated $8.05M increase.
  • EcoR1 Capital's biggest Q3 2016 reduction was Cytokinetics, cutting an estimated $13.5M.
  • EcoR1 Capital fully exited Travere Therapeutics in Q3 2016, selling an estimated $21.8M.
  • EcoR1 Capital's ten largest holdings make up 67% of its $326M portfolio in Q3 2016.
  • EcoR1 Capital opened 15 new positions and closed 15 in Q3 2016.
  • EcoR1 Capital's portfolio value rose 28% quarter-over-quarter to $326M.

Based on EcoR1 Capital's 13F filing for Q3 2016, filed 14 Nov 2016.